4000-520-616
欢迎来到免疫在线！(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
产品库 品牌馆 现货促销 技术交流 新闻动态 联系我们
bdbiosciences
主营：主营：医疗设备、医疗耗材、实验仪器、抗体、试剂、诊断等产品
咨询热线电话
4000-520-616
公司首页 公司介绍 产品中心 新闻动态 联系方式 在线下单
当前位置： 首页 > 产品中心 > peptide > BD Biosciences/CD3 FITC/Anti-HLA-DR PE/20 µL/340048
商品详细BD Biosciences/CD3 FITC/Anti-HLA-DR PE/20 µL/340048
BD Biosciences/CD3 FITC/Anti-HLA-DR PE/20 µL/340048
BD Biosciences/CD3 FITC/Anti-HLA-DR PE/20 µL/340048
商品编号： 340048
品牌： bdbiosciences
市场价： ¥0.00
美元价： 0.00
产地： 美国(厂家直采)
公司：
产品分类： 多肽合成
公司分类： peptide
联系Q Q： 3392242852
电话号码： 4000-520-616
电子邮箱： info@ebiomall.com
立即询价
商品介绍
Product DetailsRecommended AssayReferences

Description

Becton Dickinson Immunocytometry Systems (BDIS) Simultest™ CD3/Anti-HLA-DR (Leu™-4/Anti-HL A-DR) is a two-color direct immunofluorescence reagent for enumerating percentages of mature human activated T lymphocytes in erythrocyte-lysed whole blood (LWB).

Contents

SpecificityCloneFormatIsotypeEntrez Gene ID
CD3SK7 (also known as Leu-4)FITCIgG1, κ916
HLA-DRL243PEIgG2a, κ0
Resources & Tools
SpectrumViewerDownload TDSDownload MSDS
Preparation and Storage

1. For in vitro diagnostic use.

2. When stored at 2° to 8°C, the antibody reagent is stable until the expiration date shown on the label. Do not use after the expiration date.

3. The antibody reagent should not be frozen or exposed to direct light during storage or during incubation with cells. Keep the reagent vial dry.

4. Alteration in the appearance of the reagent, such as precipitation or discoloration, indicates instability or deterioration. In such cases, the reagent should not be used.

5. The antibody reagent contains sodium azide as a preservative; however, care should be taken to avoid microbial contamination, which may cause erroneous results.

  1. Bishop G, Hall B, Duggin G, Horvath J, Sheil A, Tiller D. Immunopathology of renal allograft rejection analyzed with monoclonal antibodies to mononuclear cell markers. Kidney Internat. 1986;29:708-717.

  2. Bogner J, Matuschke B, Hienrich B, Schreiber M, Nerl C, Goebel F. Expansion of activated T lymphocytes (CD3+HLA-DR+) detectable in early stages of HIV-1 infection. Klin Wochenschr. 1990;68:393-396.

  3. Brenner M, Groh V, Porcelli A, et al. Plenary papers: Structure and distribution of the human T-cell receptor. In: Knapp W, Dörken B, Gilks W, et al, eds. Leucocyte Typing IV: White Cell Differentiation Antigens. 1989:1049-1053.

  4. Brodsky F. A matrix approach to human class II histocompatibility antigens: reactions of four monoclonal antibodies with the products of nine haplotypes. Immunogenetics. 1984;19:179-194.

  5. Clevers H, Alarcón B, Wileman T, Terhorst C. The T cell receptor-CD3 complex: A dynamic protein ensemble. Annual Rev Immunol. 1988;(6):629.

  6. Edwards J, Durant B, Jones D, Evans P, Smith J. Di erential expression of HLA Class II antigens in fetal human spleen: Relationship of HLA-DP, DQ, and DR to immunoglobulin expression. J Immunol. 1985;137:479- 490.

  7. Giorgi J. Lymphocyte subset measurements: significance in clinical medicine. In: Rose N, Friedman H, Fahey J, eds. Manual of Clinical Laboratory Immunology. Washington, DC: American Society for Microbiology; 1986:236-246.

  8. Haynes B. β2-interferon/B Leukocyte Typing II: Human T Lymphocytes. 1986:3-30.

  9. Jackson A, Warner N. Preparation, staining, and analysis by flow cytometry of peripheral blood leukocytes. In: Rose N, Friedman H, Fahey J, eds. Manual of Clinical Laboratory Immunology. Washington, DC: American Society for Microbiology; 1986:226-235.

  10. Kan E, Wang C, Wang L, Evans R. Noncovalently bonded subunits of 22 and 28 kd are rapidly internalized by T cells reacted with Anti-Leu-4 antibody. J Immunol. 1983;131:536-539.

  11. Knowles R. Immunochemical analysis of the T cell-specific antigens. In: Reinherz E, Haynes B, Nadler L, Bernstein I, eds. Leukocyte Typing II: Human T Lymphocytes. 1986:259-288.

  12. Lampson L, Levy R. Two populations of Ia-like molecules on a human B cell line. J Immunol. 1980;125:293-299.

  13. Ledbetter J, Evans R, Lipinski M, Cunningham-Rundles C, RA G, Herzenberg L. Evolutionary conservation of surface molecules that distinguish T lymphocyte helper/inducer and T cytotoxic/ suppressor subpopulations in mouse and man. J Exp Med. 1981;153:310-323.

  14. Legendre C, Schiffrin A, Weitzner G, Colle E, Guttmann R. Legendre C, Schiffrin A, Weitzner G, Colle E, Guttmann R. Diabetes. 1988;37:792-795.

  15. Levacher M, Tallet S, Dazza M, Dournon E, Rouveix B, Pocidalo J. T activation marker evaluation in ARC patients treated with AZT: Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS. Clin Exp Immunol. 1990;81:177-182.

  16. National Committee for Clinical Laboratory Standards. Clinical Applications of Flow Cytometry: Quality Assurance and Immunophenotyping of Peripheral Blood Lymphocytes; Tentative Guideline (H42-T). 1992

  17. National Committee for Clinical Laboratory Standards. Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture (H3-A3). 1991

  18. Prince H, Hirji K, Waldbeser L, Plaeger-Marshall S, Kleinman S, Lanier L. Influence of racial background on the distribution of T cell subsets and Leu-11-positive lymphocytes in healthy blood donors. Diag Immunol. 1985;3:33-37.

  19. Reichert T, DeBruyère M, Deneys V, et al. Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopath. 1991;60:190-208.

  20. Stites D, Casavant C, McHugh T, et al. Flow cytometric analysis of lymphocyte phenotypes in AIDS using monoclonal antibodies and simultaneous dual immunofluorescence. Clin Immunol Immunopathol. 1986;38:161-177.

  21. Terstappen L, Hollander Z, Meiners H, Loken M. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J Leuk Biol. 1990;48:138-148.

  22. Tomkinson B, Wagner D, Nelson D, Sullivan J. Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol. 1987;139:3802-3807.

  23. van Dongen J, Krissansen G, Wolvers-Tettero I, et al. Cytoplasmic expression of the CD3 antigen as a diagnostic marker for immature T-cell malignancies. Blood. 1988;71:603-612.

  24. Vanham G, Kestens L, Gigase P, et al. Evidence for circulating activated cytotoxic T cells in HIV-infected subjects before the onset of opportunistic infections. Clin Exp Immunol. 1990;82:3-9.

  25. Warnke R, Levy R. Detection of T and B cell antigens hybridoma monoclonal antibodies: a biotin-avidin-horseradish peroxidase method. J Histochem Cytochem. 1980;28:771-776.

品牌介绍
BD是世界上最大的生产和销售医疗设备、医疗系统和试剂的医疗技术公司之一。致力于提高全世界人类的健康水平。BD专注于改进药物治疗，提高传染性疾病诊断的质量和速度，推进新型药物和疫苗的研究与发现。BD公司具有强大的研发能力和世界上最棘手的多种疾病进行斗争的能力。公司于1897年在纽约成立，总部位于美国新泽西州的富兰克林湖，业务遍及全球。公司的业务可分为BD医疗、BD诊断、BD生物科学三大类，生产销售包括医用耗材、实验室仪器、抗体、试剂、诊断等产品。公司的服务对象包括医疗机构，生命科学研究所，临床实验室，工业单位和普通大众。BD has state-of-the-art facilities around the globe that provide an environment that enables our highly talented workforce to be the best at their professions. We hire associates who have a passion and commitment to advancing the world of health. We are always seeking great people to join our company on its journey to greatness.BDRat Granulocytes Pure RP-1  500ug550002BDMs Ig Kpa Lgt Chain FITC 187.1  500ug550007BDICC Fixation Buffer 100mL550011BDMs CD210 NALE 1B1.3a 500ug550019BDMs CD51 Pure RMV-7 100ug550026BDMs CD5 APC 53-7.3 100ug550037BDHu CD62E PE-Cy5 68-5H11 100Tst550041BDHu CD95 Pure EOS9.1  100ug550052BDHam IgG2 Kpa ItCl FITC B81-3 250ug550057BDMs Crry/p65 Pure 1F2 100ug550059BDMs IL-4 Recom Protein 10ug550068BDMs IL-2 Recom Protein 20ug550070BDHu IL-6 Recom Protein 10ug550072BDHu MIP-1 Bta PE D21-1351 100ug550082BDMs IgG1 PE A85-1 100ug550084BDHam IgG2 Kpa ItCl PE B81-3 100ug550086BDHu CD142 Pure HTF-1 100ug550254BDHu CD1d PE CD1d42 100Tst550256BDHu CD73 PE AD2 100Tst550258BDHu CD103 FITC Ber-ACT8 100Tst550260BDMs CD11c APC HL3 100ug550268BDMs CD72b/c Aloatg PE JY/93 100ug550270BDRat CD32 Pure D34-485 500ug550272BDRat CD32 NALE D34-485 500ug550274BDMs CD3e IHC Pure 145-2C11 1mL550277BDMs CD4 IHC Pure H129.19 1mL550280BDMs CD8a IHC Pure 53-6.7 1mL
公司介绍
BD是世界上最大的生产和销售医疗设备、医疗系统和试剂的医疗技术公司之一。致力于提高全世界人类的健康水平。BD专注于改进药物治疗，提高传染性疾病诊断的质量和速度，推进新型药物和疫苗的研究与发现。BD公司具有强大的研发能力和世界上最棘手的多种疾病进行斗争的能力。公司于1897年在纽约成立，总部位于美国新泽西州的富兰克林湖，业务遍及全球。公司的业务可分为BD医疗、BD诊断、BD生物科学三大类，生产销售包
品牌分类
HIV Reagent Kits Stem Cell Enumeration BD Multicheck™ Control Other Species Cell Separation Reagents BD Facsunt™ 控制套件 Single-Color Antibodies BD™ Stem Cell Control Kit Sample Multiplexing Reagents 纯化抗体
显示分类
联络我们
服务热线：4000-520-616
（限工作日9:00-18:00）
QQ ：1570468124
手机：18915418616
快速导航：
总部地址：
江苏省苏州市工业园区星湖街218号 苏州生物医药产业园一期（生物纳米园）A4-216(邮编：215125)
工作时间：周一至周五9:00~18:00
技术支持：
短信：18915418616
服务热线：
4000-520-616（全国）
☏  0512-67156496（苏州）
版权信息：
©  2015-2022 苏州蚂蚁淘生物科技有限公司 版权所有 中国
网站备案：
友情链接：
免责声明：
本站有部分内容来自互联网，如无意中侵犯了某个媒体 、公司 、企业或个人等的知识产权，请来电或致函告之，
本网站将在规定时间内给予删除等相关处理。
扫描二维码关注官方微信
获取最新促销及产品信息